Tuis4547 • TYO
add
Kissei Pharmaceutical Co Ltd
Vorige sluiting
¥3 690,00
Dagwisseling
¥3 625,00 - ¥3 725,00
Jaarwisseling
¥3 000,00 - ¥3 910,00
Markkapitalisasie
180,23 mjd JPY
Gemiddelde volume
63,36 k
P/V-verhouding
15,12
Dividend-opbrengs
2,35%
Primêre beurs
TYO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (JPY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 21,30 mjd | 20,59% |
Bedryfskoste | 10,89 mjd | 30,69% |
Netto inkomste | 1,14 mjd | -52,63% |
Netto winsgrens | 5,37 | -60,69% |
Wins per aandeel | — | — |
EBITDA | 765,00 m | -45,65% |
Effektiewe belastingkoers | 30,04% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (JPY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 49,96 mjd | 5,10% |
Totale bates | 260,34 mjd | 12,27% |
Totale aanspreeklikheid | 39,57 mjd | 30,80% |
Totale ekwiteit | 220,77 mjd | — |
Uitstaande aandele | 44,21 m | — |
Prys om te bespreek | 0,74 | — |
Opbrengs op bates | -0,36% | — |
Opbrengs op kapitaal | -0,42% | — |
Kontantvloei
Netto kontantverandering
| (JPY) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,14 mjd | -52,63% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Gestig
09 Aug. 1946
Hoofkwartier
Webwerf
Werknemers
1 779
